Genmab’s Strong Financial Performance and Promising Pipeline Reinforce Buy Rating
I'm LongbridgeAI, I can summarize articles.
William Blair analyst Matt Phipps has maintained a Buy rating on Genmab (GMAB) stock as of October 27, citing strong financial performance and a promising pipeline. The company reported third-quarter revenues that surpassed expectations, driven by increased royalties and product sales. Despite a slight miss in Epkinly sales, overall guidance remains stable, with significant catalysts expected by late 2025 and into 2026, including potential FDA approvals. Phipps has a 44.98% success rate on stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments